{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Cancer&page=21",
    "query": {
      "condition": "Advanced Cancer",
      "page": 21
    },
    "page_size": 10
  },
  "pagination": {
    "page": 21,
    "page_size": 10,
    "total_count": 9795,
    "total_pages": 980,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Cancer&page=22&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Cancer&page=20&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-23T07:36:16.142Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03154281",
      "title": "Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer",
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "niraparib",
          "type": "DRUG"
        },
        {
          "name": "everolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Avera McKennan Hospital & University Health Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2017-07-26",
      "completion_date": "2023-05-01",
      "has_results": true,
      "last_update_posted_date": "2024-08-01",
      "last_synced_at": "2026-10-23T07:36:16.142Z",
      "location_count": 1,
      "location_summary": "Sioux Falls, South Dakota",
      "locations": [
        {
          "city": "Sioux Falls",
          "state": "South Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03154281"
    },
    {
      "nct_id": "NCT02072486",
      "title": "Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Advanced Adult Hepatocellular Carcinoma",
        "Localized Non-Resectable Adult Hepatocellular Carcinoma",
        "Stage III Childhood Hepatocellular Carcinoma",
        "Stage IIIA Hepatocellular Carcinoma",
        "Stage IIIB Hepatocellular Carcinoma",
        "Stage IIIC Hepatocellular Carcinoma",
        "Stage IV Childhood Hepatocellular Carcinoma",
        "Stage IVA Hepatocellular Carcinoma",
        "Stage IVB Hepatocellular Carcinoma"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Sorafenib Tosylate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 30,
      "start_date": "2013-11-18",
      "completion_date": "2020-07-19",
      "has_results": false,
      "last_update_posted_date": "2022-07-25",
      "last_synced_at": "2026-10-23T07:36:16.142Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02072486"
    },
    {
      "nct_id": "NCT01356173",
      "title": "Evaluating the Safety and Tolerability of GDC-0349 in Patients With Locally Advanced or Metastatic Solid Tumors or Non Hodgkin's Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-Hodgkin's Lymphoma, Solid Tumor"
      ],
      "interventions": [
        {
          "name": "GDC-0349",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2011-06",
      "completion_date": "2012-12",
      "has_results": false,
      "last_update_posted_date": "2016-11-02",
      "last_synced_at": "2026-10-23T07:36:16.142Z",
      "location_count": 1,
      "location_summary": "Scottsdale, Arizona",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01356173"
    },
    {
      "nct_id": "NCT00089856",
      "title": "GVAX® Vaccine for Prostate Cancer vs Docetaxel & Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Immunotherapy with allogeneic prostate vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Chemotherapy (Taxotere and prednisone)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Cell Genesys",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 626,
      "start_date": "2004-07",
      "completion_date": "2008-10",
      "has_results": false,
      "last_update_posted_date": "2008-11-05",
      "last_synced_at": "2026-10-23T07:36:16.142Z",
      "location_count": 83,
      "location_summary": "Alabaster, Alabama • Anchorage, Alaska • Glendale, Arizona + 71 more",
      "locations": [
        {
          "city": "Alabaster",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tuscon",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00089856"
    },
    {
      "nct_id": "NCT07825051",
      "title": "Healing Gardens: Leveraging Serious Games to Deliver Accessible Pain-CBT and Pharmacologic Support for Patients With Advanced Cancer Managing Pain",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Advanced Cancer",
        "Cancer Pain",
        "Chronic Pain"
      ],
      "interventions": [
        {
          "name": "Healing Gardens content development/refinement activities",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Healing Gardens serious game",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 46,
      "start_date": "2027-02-13",
      "completion_date": "2030-06-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-17",
      "last_synced_at": "2026-10-23T07:36:16.142Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts • Weymouth, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Weymouth",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07825051"
    },
    {
      "nct_id": "NCT02637531",
      "title": "A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors (Part A/B/C/D)",
        "Non-small Cell Lung Cancer (Part E)",
        "Melanoma (Part E)",
        "Squamous Cell Cancer of the Head and Neck (Part E)",
        "Triple Negative Breast Cancer (Part F)",
        "Adrenocortical Carcinoma (Part G)",
        "Mesothelioma (Part G)",
        "High-circulating Myeloid-derived Suppressor Cells (Part H)"
      ],
      "interventions": [
        {
          "name": "IPI-549 (eganelisib)",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Infinity Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 219,
      "start_date": "2015-12",
      "completion_date": "2022-12",
      "has_results": false,
      "last_update_posted_date": "2022-04-04",
      "last_synced_at": "2026-10-23T07:36:16.142Z",
      "location_count": 11,
      "location_summary": "San Diego, California • Santa Monica, California • Port Saint Lucie, Florida + 6 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Port Saint Lucie",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02637531"
    },
    {
      "nct_id": "NCT03281902",
      "title": "Genetic Analysis in Blood and Tumor Samples From Patients With Advanced or Metastatic Estrogen Receptor Positive and HER2 Negative Breast Cancer Receiving Palbociclib and Endocrine Therapy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Advanced Breast Carcinoma",
        "Locally Advanced Breast Carcinoma",
        "Metastatic Breast Carcinoma",
        "Recurrent Breast Carcinoma",
        "Stage III Breast Cancer AJCC v7",
        "Stage IIIA Breast Cancer AJCC v7",
        "Stage IIIB Breast Cancer AJCC v7",
        "Stage IIIC Breast Cancer AJCC v7",
        "Stage IV Breast Cancer AJCC v6 and v7"
      ],
      "interventions": [
        {
          "name": "Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 68,
      "start_date": "2017-11-13",
      "completion_date": "2028-03-04",
      "has_results": false,
      "last_update_posted_date": "2026-06-09",
      "last_synced_at": "2026-10-23T07:36:16.142Z",
      "location_count": 3,
      "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03281902"
    },
    {
      "nct_id": "NCT01473095",
      "title": "Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor",
        "Malignant Lymphoma",
        "Tumor"
      ],
      "interventions": [
        {
          "name": "ARQ 092",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 120,
      "start_date": "2011-11",
      "completion_date": "2017-08-07",
      "has_results": false,
      "last_update_posted_date": "2017-10-23",
      "last_synced_at": "2026-10-23T07:36:16.142Z",
      "location_count": 7,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Miami, Florida + 3 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01473095"
    },
    {
      "nct_id": "NCT02925533",
      "title": "Ph 1B B-701 in Combination With Pembrolizumab in Metastatic Transitional Cell Carcinoma of the Urothelial Tract",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "B-701",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mark Pomerantz, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "18 Years to 18 Years"
      },
      "enrollment_count": 1,
      "start_date": "2016-12-14",
      "completion_date": "2017-06",
      "has_results": false,
      "last_update_posted_date": "2017-06-27",
      "last_synced_at": "2026-10-23T07:36:16.142Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02925533"
    },
    {
      "nct_id": "NCT00455052",
      "title": "A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Small Cell Lung Cancer",
        "Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "XMT-1001",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mersana Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2011-03",
      "completion_date": "2011-12",
      "has_results": false,
      "last_update_posted_date": "2018-01-31",
      "last_synced_at": "2026-10-23T07:36:16.142Z",
      "location_count": 12,
      "location_summary": "Scottsdale, Arizona • Denver, Colorado • Indianapolis, Indiana + 9 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00455052"
    }
  ]
}